Drugs / KUX-1151
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02190786 | ? → Mar 2015 | — | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-12-24 | Pfizer | Kissei Announces Licensing Agreement with Pfizer Inc. for KUX-1151, a Novel Investigational Therapy for Gout and Hyperuricemia pfizer.com ↗ |
| 2013-12-24 | Kissei Pharmaceutical Co., Ltd. | 新規痛風・高尿酸血症治療薬「KUX-1151」のファイザー社への技術導出契約締結のお知らせ kissei.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KUX-1151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02190786 ↗ |
| Route | Oral | “multiple oral administration of KUX-1151” NCT02190786 ↗ |